Business5 sources
Eli Lilly partners with Hims & Hers to sell weight-loss drugs
- Eli Lilly's weight-loss drug Zepbound is a significant growth driver for the company.
- Hims & Hers will not compound GLP-1 medications like Zepbound in the future.
- Eli Lilly's stock price increased by about 6% following the announcement.
- Hims & Hers' stock rallied due to the agreement with Eli Lilly.
- The partnership aims to reach more weight-loss drug patients.
Timeline
Lilly to sell obesity drugs on Hims & Hers site
Eli Lilly announced it will sell its obesity drugs directly on Hims & Hers' website.
Hims & Hers struck a GLP-1 deal with Lilly
Hims & Hers Health signed a deal with Eli Lilly to sell GLP-1 medications like Zepbound.
Latest
Lilly's stock price up 6% after third-quarter update
Eli Lilly's stock price rose about 6% following an excellent third-quarter update.
Articles (6)
The Motley Fool·
Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?
Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence
MarketWatch·
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Reuters·
Lilly to sell obesity drugs directly on Hims & Hers site
Bloomberg·
Lilly, Hims Join Forces to Reach More Weight-Loss Drug Patients
Barron's·
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement